It is exhausting to sugarcoat the present state of fairness markets and the broader financial system. Issues do not look good. Inflation, a possible recession on the best way, geopolitical tensions, and provide chain points are simply a few of the challenges we face. With all that occurring, it is perhaps tempting to surrender on investing in shares proper now.

Nevertheless, it is value noting that some firms are doing simply nice, even amid all these troubles. Let us take a look at two such firms within the biotech area: Vertex Prescription drugs (VRTX 4.79%) and Exelixis (EXEL 0.37%). These drugmakers have accomplished a superb job of defying the market sell-off this yr, no less than to date. Here is why they may proceed alongside that path.

VRTX knowledge by YCharts.

1. Vertex Prescription drugs

Vertex Prescription drugs’ shares have soared 24% yr thus far regardless of the macroeconomic headwinds in its approach. The biotech owes that partially to its dominance available in the market for medicine that deal with the underlying causes of cystic fibrosis (CF), an space by which Vertex is the one recreation on the town.

Income and earnings proceed to develop for Vertex due to its CF franchise. However the market is forward-looking. And the biotech’s long-term prospects past CF are additionally taking part in a big position in its efficiency this yr. Vertex is growing a number of thrilling medicine that would change into extremely profitable.

Let’s contemplate two. First, there’s VX-548, a possible therapy for acute and neuropathic ache (ache attributable to nerve harm). Though ache remedies exist, they’re restricted. Opioids are an ordinary possibility for acute ache, however as we realized from the latest opioid epidemic, their use and misuse can have profoundly detrimental penalties for whole communities.

Different medicines undergo from drawbacks as effectively. Acetaminophen is a well-liked ache remedy offered beneath a number of model names, together with the all too acquainted Tylenol. Taking an excessive amount of acetaminophen is the main explanation for acute liver failure within the U.S.

Vertex argues that there hasn’t been a significant breakthrough on this therapeutic space for many years, and that sufferers have a dire want for brand spanking new choices. The corporate plans on beginning a section three research for VX-548 within the fourth quarter.

Second, there may be VX-880, a possible remedy for sort 1 diabetes. This targets one of many underlying causes of this situation: sufferers’ incapacity to supply insulin. Vertex has launched encouraging knowledge from two sufferers in an ongoing section half of research of VX-880.

The primary affected person’s glucose time in vary (TIR) — how lengthy an individual’s blood sugar stays inside sure parameters — elevated from 40.1% earlier than therapy to 99.9% 270 days post-treatment, some extent by which the affected person achieved insulin independence. The second noticed glucose TIR improve from 35.9% to 51.9% at day 150, and the affected person wanted 30% much less exterior insulin. VX-880 nonetheless has a protracted approach to go, however focusing on the underlying causes of a illness is an method that has served Vertex effectively earlier than.

In all chance, the corporate’s subsequent launch will likely be exa-cel, a possible one-time healing therapy for sickle cell illness and transfusion-dependent beta-thalassemia, two blood problems with few remedy choices. Vertex plans to ship purposes for exa-cel within the U.S. and Europe by year-end, with potential launches in these respective markets occurring someday subsequent yr.

Throughout the subsequent 5 years, anticipate the corporate to proceed producing income from its CF merchandise whereas it advantages from newer therapies. Meaning greater income, greater earnings, and a stable stock-price efficiency. These components make Vertex Prescription drugs a high inventory to purchase proper now.

2. Exelixis

Exelixis is a biotech that focuses on most cancers remedies. That is not a nasty place to be. Whereas oncology is a extremely aggressive therapeutic space within the biotech trade — with most of the largest drugmakers current on this discipline — it is also one of many largest by whole gross sales and one of many fastest-growing. Exelixis’s fundamental product is Cabometyx, which treats some types of kidney most cancers and liver most cancers.

This single product has racked up regulatory approvals one after one other, and it continues to take action. A significant new indication it earned final yr — as a first-line mixture remedy for superior renal cell carcinoma (a type of kidney most cancers) — was instrumental in driving Exelixis’ income and earnings upward.

There’s extra the place that got here from as Cabometyx is present process dozens of medical trials, both as a stand-alone remedy or a possible mixture therapy. Final month, the corporate launched constructive outcomes from a section three medical trial for its crown jewel.

Exelixis is trying to increase its income base. In June, it began a section three medical trial for its candidate XL092 as a possible therapy for metastatic colorectal most cancers. This type of most cancers is the third most typical and the third-deadliest within the U.S., and it’s difficult to deal with after it has metastasized, which is when about 25% of instances are recognized.

Exelixis has different packages in early-stage research. Diversifying over a number of therapeutic areas has its perks, however Exelixis’ laser-focused method to growing novel most cancers therapies has been profitable up to now, due to Cabometyx. I anticipate the corporate to proceed reaping the rewards of those efforts as its present packages ultimately repay.